IBRX
ImmunityBio·NASDAQ
--
--(--)
--
--(--)
IBRX fundamentals
ImmunityBio (IBRX) released its earnings on Feb 23, 2026: revenue was 38.28M (YoY +406.95%), missed estimates; EPS was -0.06 (YoY +33.33%), beat estimates.
Revenue / YoY
38.28M
+406.95%
EPS / YoY
-0.06
+33.33%
Report date
Feb 23, 2026
IBRX Earnings Call Summary for Q4,2025
- 700% Revenue Growth: ANKTIVA net product revenue reached $113 million in 2025, up from $14.1 million in 2024.
- Global Expansion: 33-country footprint, including EU and Saudi Arabia approvals for bladder and lung cancer.
- Innovative Platform: BioShield combines ANKTIVA with checkpoint inhibitors, cell therapies, and vaccines to treat cancer and lymphopenia.
- AI-Driven Manufacturing: NantLeonardo platform scales cell therapy production at low cost.
- Lung Cancer Breakthrough: Saudi Arabia first to approve ANKTIVA + checkpoint inhibitors for metastatic NSCLC.
EPS
Actual | -0.19 | -0.26 | -0.27 | -0.32 | -0.19 | -0.36 | -0.2 | -0.2 | -0.14 | -0.09 | -0.15 | -0.1 | -0.06 | ||||
Forecast | -0.17 | -0.22 | -0.28 | -0.27 | -0.235 | -0.255 | -0.18 | -0.195 | -0.16 | -0.178 | -0.2 | -0.128 | -0.108 | -0.0765 | |||
Surprise | 0.00% | 0.00% | 0.00% | -11.76% | -18.18% | 0.00% | 0.00% | -36.17% | +25.49% | -100.00% | -2.56% | -25.00% | +21.35% | +55.00% | -17.19% | +7.41% | +21.57% |
Revenue
Actual | -- | -- | -- | 21.00K | 14.00K | -- | 400.00K | 41.00K | 82.00K | 119.50K | 0 | 1.00M | 6.11M | 7.55M | 16.52M | 26.43M | 38.28M |
Forecast | -- | -- | -- | 0 | 25.00K | 118.00K | 25.00K | 0 | 0 | 25.00K | 62.50K | 14.71M | 2.92M | 9.63M | 15.97M | 23.15M | 38.36M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | -44.00% | 0.00% | +1500.00% | 0.00% | 0.00% | +378.00% | -100.00% | -93.20% | +108.75% | -21.54% | +3.39% | +14.16% | -0.20% |
Earnings Call
You can ask Aime
What were the key takeaways from ImmunityBio’s earnings call?What is ImmunityBio's gross profit margin?What were the key takeaways from ImmunityBio's earnings call?What factors drove the changes in ImmunityBio's revenue and profit?What is the revenue and EPS growth rate for ImmunityBio year over year?What guidance did ImmunityBio's management provide for the next earnings period?What is the market's earnings forecast for ImmunityBio next quarter?What is ImmunityBio's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
